Celgene Corp (NASDAQ:CELG) 2017 Q4 Sentiment Change, Now at 0.83

May 17, 2018 - By Alma Kearns

Celgene Corporation (NASDAQ:CELG) Corporate Logo

Positions for Celgene Corp (NASDAQ:CELG)

In 2017 Q4 Celgene Corp (NASDAQ:CELG) big money sentiment decreased to 0.83, revealed SEC filings. That’s down -0.34, from 2017Q3’s 1.17. 529 investment professionals started new or increased holdings, while 634 cut down and sold equity positions in Celgene Corp so the sentiment is negative. Funds own 561.38 million shares, down from 603.99 million shares in 2017Q3. Funds holding Celgene Corp in top 10 changed to 38 from 119 for a decrease of 81. In total 156 funds closed positions, 478 reduced and 411 increased. Also 118 funds bought new Celgene Corp stakes.

Biggest Celgene Corp Investors

Birchview Capital Lp owns 744,051 shares in Celgene Corp as of 2017 Q4. As of 2017 Q4, 2.11 million shares of Celgene Corp are owned by Oaktop Capital Management Ii L.P.. Selkirk Management Llc reported 260,000 shares. Bb Biotech Ag revealed 3.42 million shares position in Celgene Corp. The United Kingdom-based fund Edinburgh Partners Ltd holds 315,906 shares or 8.7% of their stocks portfolio.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The company has $59.09 billion market cap. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.22.35 is the P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

CELG reached $81.36 during the last trading session after $0.62 change.Celgene Corporation has volume of 6.04M shares. Since May 17, 2017 CELG has declined 31.28% and is downtrending. CELG underperformed the S&P 500 by 42.83%.

On July, 26 is anticipated Celgene Corporation (NASDAQ:CELG)’s earnings report, Faxor reports. earnings per share of $1.87 is 11.31 % up from 2017’s $1.68 EPS. This could be $1.36B profit for CELG assuming the current $1.87 earnings per share will become reality. Wall Street sees 16.15 % EPS growth as of July, 26.

Atwood And Palmer owns 161,008 shs. General Amer holds 1.67% or 165,000 shs in its capital. Boys Arnold And Com holds 0.29% or 18,186 shs. Massmutual Tru Co Fsb Adv holds 0.03% or 21,063 shs in its capital. Zwj Counsel Incorporated holds 1.74% of its capital in Celgene Corporation (NASDAQ:CELG) for 211,197 shs. Baldwin Invest Mngmt Limited Co invested in 0.74% or 19,960 shs. Wealthfront accumulated 20,965 shs. Invest House Limited Liability reported 72,411 shs. 7,875 were reported by Palisade Capital Mngmt Lc Nj. Hm Payson And Company, Maine-based fund reported 109,574 shs. Stonebridge Mngmt, a California-based fund reported 2,098 shs. Jnba Fincl Advsr owns 0.01% invested in Celgene Corporation (NASDAQ:CELG) for 530 shs. Amer Money Limited Liability Co holds 15,825 shs. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0.32% or 342,640 shs. Canada Pension Plan Investment Board stated it has 0.42% of its capital in Celgene Corporation (NASDAQ:CELG).

Celgene Corporation registered $3.58 million net activity with 1 insider purchase and 3 insider sales since February 8, 2018. $851,093 worth of Celgene Corporation (NASDAQ:CELG) shs were sold by LOUGHLIN JAMES J. $299,594 worth of Celgene Corporation (NASDAQ:CELG) was bought by Alles Mark J. On Thursday, February 15 the insider KAPLAN GILLA sold $1.77 million.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

In total 20 analysts cover Celgene (NASDAQ:CELG). “Buy” rating has 13, “Sell” are 0, while 7 are “Hold”. 65% are bullish. With $152.0 highest and $90 lowest PT Celgene has $122 average PT or 49.95% above the current ($81.36) price. 35 are the (NASDAQ:CELG)’s analyst reports since December 8, 2017 according to StockzIntelligence Inc. On Thursday, December 21 the rating was maintained by Piper Jaffray with “Hold”. On Wednesday, December 13 the company was maintained by Leerink Swann. On Tuesday, January 23 the rating was maintained by RBC Capital Markets with “Buy”. On Friday, April 13 the firm has “Equal-Weight” rating given by Morgan Stanley. On Monday, January 8 Stifel Nicolaus maintained Celgene Corporation (NASDAQ:CELG) rating. Stifel Nicolaus has “Buy” rating and $130.0 target. On Monday, May 7 the rating was maintained by Morgan Stanley with “Equal-Weight”. On Tuesday, January 23 the company was maintained by Canaccord Genuity. On Monday, May 7 the stock of Celgene Corporation (NASDAQ:CELG) earned “Outperform” rating by RBC Capital Markets. On Wednesday, February 28 the stock has “Outperform” rating by Credit Suisse. In Thursday, January 25 report SunTrust maintained it with “Buy” rating and $139.0 target.

For more Celgene Corporation (NASDAQ:CELG) news announced recently go to: Fool.com, Seekingalpha.com, Seekingalpha.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Celgene Starts the Year With a Bang” announced on May 14, 2018, “Generic Revlimid Could Sink Celgene” on May 16, 2018, “My 2 Cents On The Ozanimod Saga” with a publish date: May 15, 2018, “Nohla Therapeutics Announces Closing of $45 Million Series B Financing” and the last “Celgene Earnings Preview” with publication date: April 30, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: